Impact of substance P receptor antagonism on the serotonin and norepinephrine systems: relevance to the antidepressant/anxiolytic response
- PMID: 15173897
- PMCID: PMC400690
Impact of substance P receptor antagonism on the serotonin and norepinephrine systems: relevance to the antidepressant/anxiolytic response
Abstract
Substance P (neurokinin-1 [NK1]) receptor antagonists appear to be effective antidepressant and anxiolytic agents, as indicated in 3 double-blind clinical trials. In laboratory animals, they promptly attenuate the responsiveness of serotonin (5-hydroxytryptamine [5-HT]) and norepinephrine (NE) neurons to agonists of their cell-body autoreceptors, as is the case for some antidepressant drugs that are currently in clinical use. Long-term, but not subacute, antagonism of NK1 receptors in rats increases 5-HT transmission in the hippocampus, a property common to all antidepressant treatments tested thus far. This enhancement seems to be mediated by a time-dependent increase in the firing rate of 5-HT neurons. Mice with the NK1 receptor deleted from their genetic code also have an increased firing rate of 5-HT neurons. Taken together, these observations strongly suggest that NK1 antagonists could become a new class of antidepressant and anxiolytic agents.
Les antagonistes des récepteurs de la substance P (neurokinine-1 [NK1]) semblent efficaces comme antidépresseurs et anxiolytiques, ainsi que l'indiquent trois études cliniques à double insu. Chez des animaux de laboratoire, ces agents atténuent rapidement la réponse des neurones à sérotonine (5-hydroxytryptamine [5-HT]) et à norépinéphrine (NE) aux agonistes de leurs autorécepteurs du corps cellulaire, comme dans le cas de certains antidépresseurs actuellement utilisés en clinique. L'antagonisme à long terme mais non subaigu des récepteurs de la NK1 chez le rat accroÎt la transmission de la 5-HT dans l'hippocampe, caractéristique commune à tous les traitements aux antidépresseurs étudiés à ce jour. Une augmentation de la fréquence de décharge des neurones de la 5-HT liée au temps semble intervenir dans cette élévation. Les souris dont on a éliminé le récepteur de la NK1 du code génétique ont aussi une fréquence de décharge plus élevée des neurones de la 5-HT. Globalement, ces observations indiquent fortement que les antagonistes de la NK1 pourraient devenir une nouvelle catégorie d'antidépresseurs et d'anxiolytiques.
Figures







Similar articles
-
Neurokinin-1 receptor antagonists modulate brain noradrenaline and serotonin interactions.Eur J Pharmacol. 2008 Dec 14;600(1-3):64-70. doi: 10.1016/j.ejphar.2008.10.001. Epub 2008 Oct 9. Eur J Pharmacol. 2008. PMID: 18930727
-
Neurokinin 1 receptor antagonism requires norepinephrine to increase serotonin function.Eur Neuropsychopharmacol. 2007 Apr;17(5):328-38. doi: 10.1016/j.euroneuro.2006.07.004. Epub 2006 Sep 6. Eur Neuropsychopharmacol. 2007. PMID: 16950604
-
Chronic substance P (NK1) receptor antagonist and conventional antidepressant treatment increases burst firing of monoamine neurones in the locus coeruleus.Neuroscience. 2002;109(3):609-17. doi: 10.1016/s0306-4522(01)00467-5. Neuroscience. 2002. PMID: 11823070
-
Antidepressant properties of substance P antagonists: relationship to monoaminergic mechanisms?Curr Drug Targets CNS Neurol Disord. 2004 Apr;3(2):113-21. doi: 10.2174/1568007043482516. Curr Drug Targets CNS Neurol Disord. 2004. PMID: 15078186 Review.
-
Effect of neurokinin-1 receptor antagonists on serotoninergic, noradrenergic and hippocampal neurons: comparison with antidepressant drugs.Peptides. 2005 Aug;26(8):1383-93. doi: 10.1016/j.peptides.2005.03.032. Epub 2005 Apr 21. Peptides. 2005. PMID: 16042978 Review.
Cited by
-
Characterization of RO4583298 as a novel potent, dual antagonist with in vivo activity at tachykinin NK₁ and NK₃ receptors.Br J Pharmacol. 2011 Feb;162(4):929-46. doi: 10.1111/j.1476-5381.2010.01096.x. Br J Pharmacol. 2011. PMID: 21039418 Free PMC article.
-
Diminished neurokinin-1 receptor availability in patients with two forms of chronic visceral pain.Pain. 2013 Jul;154(7):987-96. doi: 10.1016/j.pain.2013.02.026. Epub 2013 Mar 5. Pain. 2013. PMID: 23582152 Free PMC article. Clinical Trial.
-
The Hypothalamic-Pituitary-Adrenal Axis and Serotonin Metabolism in Individual Brain Nuclei of Mice with Genetic Disruption of the NK1 Receptor Exposed to Acute Stress.Cell Mol Neurobiol. 2018 Aug;38(6):1271-1281. doi: 10.1007/s10571-018-0594-5. Epub 2018 Jun 15. Cell Mol Neurobiol. 2018. PMID: 29948553 Free PMC article.
-
Antidepressant-like effects of agomelatine, melatonin and the NK1 receptor antagonist GR205171 in impulsive-related behaviour in rats.Psychopharmacology (Berl). 2005 Oct;182(1):24-32. doi: 10.1007/s00213-005-0050-3. Epub 2005 Sep 29. Psychopharmacology (Berl). 2005. PMID: 15986188
-
The drugs don't work? antidepressants and the current and future pharmacological management of depression.Ther Adv Psychopharmacol. 2012 Oct;2(5):179-88. doi: 10.1177/2045125312445469. Ther Adv Psychopharmacol. 2012. PMID: 23983973 Free PMC article.
References
-
- Thase ME, Entsuah AR, Rudolph RL. Remission rates during treatment with venlafaxine or selective serotonin reuptake inhibitors. Br J Psychiatry 2001;178:234-41. - PubMed
-
- Thase ME, Ninan PT. New goals in the treatment of depression: moving toward recovery. Psychopharmacol Bull 2002; 36(Suppl 2):24-35. - PubMed
-
- Kramer MS, Cutler N, Feighner J, Shrivastava R, Carman J, Sramek JJ, et al. Distinct mechanism for antidepressant activity by blockade of central substance P receptors. Science 1998; 281:1640-5. - PubMed
-
- Guyenet PG, Aghajanian GK. Excitation of neurons in the nucleus locus coeruleus by substance P and related peptides. Brain Res 1977;136:178-84. - PubMed
-
- McLean S, Ganong AH, Seeger TF, Bryce DK, Pratt KG, Reynolds LS, et al. Activity and distribution of binding sites in brain of a nonpeptide substance P (NK1) receptor antagonist. Science 1991;251:437-9. - PubMed